Urothelial carcinoma of the bladder: definition, treatment and future efforts

scientific article published on 11 October 2011

Urothelial carcinoma of the bladder: definition, treatment and future efforts is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/NRUROL.2011.144
P8608Fatcat IDrelease_3l3n7kw3xvgpreo7ys4p6h3v7m
P698PubMed publication ID21989305

P2093author name stringMedscape
Gary D Steinberg
Sandip M Prasad
G Joel Decastro
P2860cites workCancer statistics, 2010Q27860525
The cancer genomeQ29547643
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessmentQ30421675
Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data baseQ30767936
Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaborationQ30991559
Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis CollaborationQ30991564
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data BaseQ33287299
An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancerQ33438009
Micropapillary bladder cancer: a review of Léon Bérard Cancer Center experienceQ33469979
Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinomaQ33670824
Multivariate analysis of the prognostic factors of primary superficial bladder cancerQ33799104
Urine cytology. It is still the gold standard for screening?Q33851115
Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analysesQ34174003
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancerQ34226107
Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term resultsQ34667307
Effects of individual-level socioeconomic factors on racial disparities in cancer treatment and survival: findings from the National Longitudinal Mortality Study, 1979-2003.Q34961124
Use of high-throughput DNA microarrays to identify biomarkers for bladder cancerQ35036724
Do mixed histological features affect survival benefit from neoadjuvant platinum‐based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group‐Directed Intergroup Study (S8710)Q35051123
Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomyQ35063376
The value of a second transurethral resection in evaluating patients with bladder tumoursQ35071427
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 statusQ35187828
Multi–Detector Row CT Urography in the Evaluation of HematuriaQ35582739
Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer.Q35604142
Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment.Q35613672
Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysisQ35624838
Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy.Q45994760
Trends in pelvic lymphadenectomy at the time of radical cystectomy: 1988 to 2004.Q46118519
Gender and geographic influence on the racial disparity in bladder cancer mortality in the US.Q46229060
Hydronephrosis as a prognostic indicator in bladder cancer patientsQ46447197
A case of relapsing secondary bladder adenocarcinoma after right colonic cancerQ46499515
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancerQ46610841
Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks.Q47594338
Conservative management of low risk superficial bladder tumorsQ48548171
Factors affecting recurrence and progression in superficial bladder tumours.Q51046351
Does the presence of muscularis propria on transurethral resection of bladder tumour specimens affect the rate of upstaging in cT1 bladder cancer?Q51738112
The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma.Q51819769
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.Q51953901
Neural network analysis of clinicopathological and molecular markers in bladder cancer.Q52082615
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.Q53263269
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].Q53462584
Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer.Q53466370
Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.Q53493936
Non-invasive papillary carcinoma of the bladder associated with carcinoma in situQ53591287
Gender differences in stage distribution of bladder cancerQ57307308
Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 TrialQ59629290
Association of Angiogenesis Related Markers With Bladder Cancer Outcomes and Other Molecular MarkersQ59649562
Can patient selection for bladder preservation be based on response to chemotherapy?Q61900098
The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinomaQ68180488
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized studyQ73798367
Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcomeQ74463742
Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patientsQ74674542
The value of a second transurethral resection in evaluating patients with bladder tumorsQ77914322
Impact of a second transurethral resection on the staging of T1 bladder cancerQ78508168
An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinomaQ78645466
Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomyQ78860560
Delaying Radical Cystectomy for Muscle Invasive Bladder Cancer Results in Worse Pathological StageQ79075055
Chemoprevention of bladder cancerQ79263915
The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancerQ79805550
Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancerQ79832999
Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experienceQ79847300
Management of clinical T1 bladder transitional cell carcinoma by radical cystectomyQ80395918
Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomyQ80450576
Outcome after radical cystectomy with limited or extended pelvic lymph node dissectionQ80553123
The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancerQ80615790
Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladderQ81441276
Advanced bladder cancer: so many drugs, so little progress : what's wrong with this picture?Q81614011
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladderQ81634328
Sex and racial differences in bladder cancer presentation and mortality in the USQ82918430
The value of a second transurethral resection for T1 bladder cancerQ82980705
Sex and race in bladder cancer: what we have learned and future directionsQ83004160
The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trialQ83116457
Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohortQ83229154
Early vs delayed radical cystectomy for 'high-risk' carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survivalQ83229181
Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment?Q83296498
Bladder cancerQ84058686
The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tablesQ84215941
Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancerQ84415859
Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer?Q84795217
Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urotheliumQ93606365
The health economics of bladder cancer: a comprehensive review of the published literature.Q35642541
Gene discovery in bladder cancer progression using cDNA microarraysQ35791851
Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience.Q35833326
Second-line intravesical therapy versus cystectomy for bacille Calmette-Guérin (BCG) failuresQ35858348
T1G3 bladder cancer--indications for early cystectomyQ35875210
Genetic and epigenetic aspects of bladder cancerQ36067118
The role of lymphadenectomy in high-grade invasive bladder cancerQ36111234
Urothelial tumorigenesis: a tale of divergent pathwaysQ36234720
Non-muscle-invasive bladder cancer: the role of radical cystectomyQ36312300
The role of taxanes in the management of bladder cancerQ36325413
Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?Q36341182
Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markersQ36363225
Genetic alterations in urothelial bladder carcinoma: an updated reviewQ36393012
Lymphovascular invasion as a prognostic tool for advanced bladder cancerQ36564692
Treatment options for BCG failures.Q36615027
New imaging modalities in bladder cancerQ36653218
Case of carcinosarcoma of urinary bladder obtained a pathologically complete response by neoadjuvant chemoradiotherapyQ36697819
Defining optimal therapy for muscle invasive bladder cancerQ36707709
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.Q36729145
Intravesical treatments of bladder cancer: review.Q36738254
Immunotherapeutic strategies for high-risk bladder cancerQ36768976
Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patientsQ36836840
Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement.Q36866916
Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experienceQ36871918
Novel strategies for treating relapsed/refractory urothelial carcinomaQ36995686
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 updateQ36997480
The Will Rogers phenomenon in urological oncologyQ36998785
Urinary markers in bladder cancerQ37046221
Nomograms for bladder cancerQ37061242
The impact of variant histology on the outcome of bladder cancer treated with curative intentQ37119414
Molecular biomarkers in urothelial bladder cancerQ37123497
Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis.Q37125906
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladderQ37158767
Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience.Q37221832
Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancerQ37314551
Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer NetworkQ37348345
Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimicsQ37380015
Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancerQ37434877
Combination of BCG and interferon intravesical immunotherapy: an update.Q37500031
Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implicationsQ37507542
Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analysesQ37676425
Are nomograms needed in the management of bladder cancer?Q37685558
Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancerQ37787119
Vinflunine in the treatment of advanced bladder cancerQ37821892
Neoadjuvant systemic therapy or early cystectomy? Single-center analysis of outcomes after therapy for patients with clinically localized micropapillary urothelial carcinoma of the bladderQ37836129
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.Q37859970
Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinomaQ38448798
Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancerQ39822041
Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG.Q39904370
Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.Q40009253
Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.Q40348441
Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter studyQ40543930
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group studyQ40731377
The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancerQ40751576
The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index.Q40854612
Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer.Q41073539
Superficial bladder cancer: the primacy of grade in the development of invasive diseaseQ41334965
High-grade hyperinvasive sarcomatoid urothelial bladder carcinoma demonstrating complete response to bladder-preserving chemoradiationQ41508463
BCAN Think Tank session 3: Prevention of bladder cancerQ43075685
Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinomaQ43294213
Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).Q43450732
Predicting recurrence and progression in non-muscle-invasive bladder cancer using European organization of research and treatment of cancer risk tables.Q44057900
Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 casesQ44271939
Selenium and bladder cancer risk: a meta-analysis.Q44325332
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancerQ44689045
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group StudyQ44870028
A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trialsQ44883456
Small cell carcinoma of the urinary bladder. The Mayo Clinic experienceQ45077919
Effective therapy for metastatic renal cancer, whither to now.Q45219473
Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancerQ45340458
Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging.Q45907687
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.Q45967681
FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.Q45992013
P433issue11
P407language of work or nameEnglishQ1860
P304page(s)631-642
P577publication date2011-10-11
P1433published inNature Reviews UrologyQ2079265
P1476titleUrothelial carcinoma of the bladder: definition, treatment and future efforts
P478volume8

Reverse relations

cites work (P2860)
Q38721568ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer
Q36739002ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.
Q38131409Alterations of DNA methylome in human bladder cancer.
Q97519531BORA regulates cell proliferation and migration in bladder cancer
Q42465565Bladder cancers arise from distinct urothelial sub-populations.
Q36272100CLASP2 is involved in the EMT and early progression after transurethral resection of the bladder tumor
Q36490303CMTM8 inhibits the carcinogenesis and progression of bladder cancer
Q38686052Cantharidin alters the expression of genes associated with the NKG2D-associated immune response in TSGH-8301 human bladder carcinoma cells
Q92744195Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis
Q91842173CircPTPRA acts as a tumor suppressor in bladder cancer by sponging miR-636 and upregulating KLF9
Q47694209Clinical Proteomics for Precision Medicine: The Bladder Cancer Case
Q39404314Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest in bladder cancer cells
Q54090828Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: A prospective, single-center study.
Q39318239Do histological variants in urothelial carcinoma of the bladder portend poor prognosis? A systematic review and meta-analysis
Q51062025Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients' prognosis.
Q35956711Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study
Q47170529Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer
Q28074732Genetic and Epigenetic Alterations in Bladder Cancer
Q46779353Inflammatory microenvironment in the initiation and progression of bladder cancer
Q41339763Insights from animal models of bladder cancer: recent advances, challenges, and opportunities
Q91670697Kinesin family member C1 accelerates bladder cancer cell proliferation and induces epithelial-mesenchymal transition via Akt/GSK3β signaling
Q34717627Knockdown of regulator of cullins-1 (ROC1) expression induces bladder cancer cell cycle arrest at the G2 phase and senescence
Q35022673Lack of decorin expression by human bladder cancer cells offers new tools in the therapy of urothelial malignancies
Q58093528Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients
Q38715315Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
Q37317523Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis
Q36557362Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma.
Q90478682MiR-362-5p, Which Is Regulated by Long Non-Coding RNA MBNL1-AS1, Promotes the Cell Proliferation and Tumor Growth of Bladder Cancer by Targeting QKI
Q35605883MicroRNA-320c inhibits tumorous behaviors of bladder cancer by targeting Cyclin-dependent kinase 6
Q33642335MicroRNAs as biomarkers associated with bladder cancer
Q35285703Modelling bladder cancer in mice: opportunities and challenges
Q26825948Normal and neoplastic urothelial stem cells: getting to the root of the problem
Q41486372Overexpression of HMGB3 protein promotes cell proliferation, migration and is associated with poor prognosis in urinary bladder cancer patients
Q36574137Overexpression of RNF2 Is an Independent Predictor of Outcome in Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy
Q44581657PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors
Q64055449PPARγ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells
Q100515374Part 1. Evaluation of epigallocatechin gallate or tannic acid formulations of hydrophobic drugs for enhanced dermal and bladder uptake or for local anesthesia effects
Q89761556Patient-Derived Xenograft Models in Urological Malignancies: Urothelial Cell Carcinoma and Renal Cell Carcinoma
Q38714374Patient-derived xenografts as in vivo models for research in urological malignancies
Q47727562Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas
Q27324419Protein Profiling of Bladder Urothelial Cell Carcinoma
Q42378347Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention
Q39038597Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors
Q33919252Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).
Q49168184Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis
Q37256055TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism
Q47670544The Stromal Niche for Epithelial Stem Cells: A Template for Regeneration and a Brake on Malignancy
Q36339910The prognostic significance of DAPK1 in bladder cancer
Q53119894Tissue Permeability Effects Associated with the Use of Mucoadhesive Cationic Nanoformulations of Docetaxel in the Bladder.
Q52602391Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.
Q43717784Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment
Q35056092Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation
Q39097235Urothelial generation and regeneration in development, injury, and cancer.
Q48225163miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression
Q90600278ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression

Search more.